Author:
Barry A L,Thornsberry C,Jones R N
Abstract
A new macrolide (A-56268) was found to be approximately twice as active as erythromycin and four to eight times more active than roxithromycin. All three macrolides were similar in their potency against anaerobes. Human plasma enhanced the antistaphylococcal activity of A-56268 and erythromycin but reduced the activities of roxithromycin and clindamycin.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference11 articles.
1. In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria;Barlam T.;Antimicrob. Agents Chemother.,1984
2. In vitro activity of rosamicin, josamycin, erythromycin, and clindamycin against P-lactamase-negative and P-lactamase-positive strains of Neisseria gonorrhoeae;Biddle J. W.;Antimicrob. Agents Chemother.,1979
3. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide;Fernandes P. B.;Antimicrob. Agents Chemother.,1986
4. Effect of carbon dioxide and pH on susceptibility of Bacteroides fragilis group to erythromycin;Hansen S. L.;Antimicrob. Agents Chemother.,1981
5. In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs;Jones R. N.;Antimicrob. Agents Chemother.,1983
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献